Clinical Trials Retatrutide: What the Research Shows and How to Join

Clinical trials retatrutide refers to the Phase 3 research program testing Eli Lilly's investigational triple-hormone drug, and the short answer is this: retatrutide is not FDA-approved, cannot be prescribed, and is only available to people who enroll in a study. The largest studies belong to the TRIUMPH program, which runs at research sites across the United States. Most people searching for retatrutide clinical trials near me are really looking for a recruiting site, a phone number, and a realistic picture of who gets in.

What Retatrutide Is and Why It Is Studied

Retatrutide, also known by the code LY3437943, is a once-weekly injectable that activates three receptors at once: GIP, GLP-1, and glucagon. The glucagon arm is what separates it from semaglutide and tirzepatide, and early research suggests it may produce larger average weight loss than either.

The drug is being studied for obesity, type 2 diabetes, and several weight-related conditions. If you have ever typed is retatrutide a glp-3 into a search bar, the honest answer is that no such receptor class exists. GLP-3 is not a recognized pharmacology term; retatrutide is a triple agonist, not a third-generation GLP-1.

Retatrutide Phase 2 Results Set the Bar

The most detailed human data published so far come from a Phase 2 trial reported in the New England Journal of Medicine in 2023. In that study, adults with obesity and without diabetes lost an average of up to 24.2% of their body weight after 48 weeks on the highest dose tested.

Weight loss was still trending downward when that trial ended, which is one reason people ask how long does retatrutide take to work. Phase 2 studies are small and cannot prove long-term safety or benefit, so those numbers are a signal, not a guarantee.

Retatrutide Phase 3 Trials: The TRIUMPH Program

Phase 3 studies are the final step before a company can apply for FDA approval. Lilly's Phase 3 program for retatrutide includes several large, randomized, double-blind trials grouped under the TRIUMPH name.

TRIUMPH-1 and TRIUMPH-4 attract the most search interest, but regulators review the full package of studies rather than one headline result.

Retatrutide Phase 3 Results: Where the Data Stand

Retatrutide phase 3 results are released as each trial finishes, not all at once. Lilly has indicated that topline TRIUMPH readouts would arrive in 2026 and beyond, so any precise number circulating online before publication should be treated as unverified.

When results do land, expect them in peer-reviewed journals and company announcements, not in screenshots from online sellers. A completed trial reports average weight change, the share of participants reaching 5%, 10%, 15%, and 20% weight loss, side effects, and discontinuation rates.

How to Find Retatrutide Clinical Trials Near You

Legitimate studies recruit through regulated channels, and the search costs nothing. Start with these steps:

1. Search ClinicalTrials.gov for retatrutide, then filter by recruiting status and distance from your ZIP code.
2. Check Lilly Trial Connect, the manufacturer's own study finder, which lists open Lilly-sponsored trials and lets you submit your information once.
3. Call academic medical centers and dedicated research clinics in your metro area and ask whether they run obesity or endocrinology trials.
4. Ask your primary care doctor or endocrinologist for a referral to a site that is enrolling.

Be skeptical of any ad promising free weight loss trials near me that requests a credit card, a membership fee, or payment for medication. Legitimate trials never charge participants for the study drug, and they never ship it to your home.

Who Is Eligible for a Retatrutide Study

Every protocol sets its own rules, but common eligibility criteria across retatrutide studies include:

• Age 18 or older, with some trials capping enrollment at 75.
• A body mass index of 30 or higher, or 27 or higher with at least one weight-related condition such as high blood pressure or high cholesterol.
• No type 1 diabetes, and no recent use of another GLP-1 or GIP drug within a washout period.
• No personal or family history of medullary thyroid cancer or MEN2, and no history of pancreatitis.
• Not pregnant or breastfeeding, and able to attend clinic visits for the length of the study, which can run a year or longer.

What Participation Actually Involves

Retatrutide studies are randomized and double-blind, which means neither you nor your study doctor chooses whether you receive the drug or a placebo. Participants get the study drug or placebo at no cost, along with lab work, weight and blood pressure checks, and dietary counseling.

The drug is given as a weekly subcutaneous injection, and retatrutide how to inject is a question that study staff answer in person during your first visit. You can leave a trial at any time for any reason, and doing so does not affect your regular medical care.

There is no retatrutide brand name yet. Because the drug is still investigational, it is identified by its code name or by a trial number.

Side Effects and Safety Signals

In Phase 2 testing, the most common side effects were gastrointestinal: nausea, diarrhea, vomiting, and constipation. These were usually mild to moderate, appeared most often during dose increases, and were the main reason some participants stopped treatment.

Because retatrutide also activates the glucagon receptor, researchers monitor heart rate, liver enzymes, and gallbladder issues closely. Anyone with a history of pancreatitis, gastroparesis, or kidney disease should discuss risks with a physician before screening.

Unapproved Retatrutide Sold Online Is Not a Trial

Many websites sell retatrutide as a research chemical, sometimes bundled with other unapproved peptides. These products are not FDA-approved, are not made under pharmaceutical quality standards, and carry no verified dose or purity.

For context, cagrilintide vs retatrutide is a comparison between an investigational amylin-based combination and a triple agonist; neither is an approved medication. Both belong in a doctor's office, not in a shopping cart.

Talk with a licensed healthcare professional about approved treatment options, and consider a clinical trial only through a verified registry or a recognized research site.